AU757945B2 - Use of cannabinoids as anti-inflammatory agents - Google Patents

Use of cannabinoids as anti-inflammatory agents Download PDF

Info

Publication number
AU757945B2
AU757945B2 AU34361/99A AU3436199A AU757945B2 AU 757945 B2 AU757945 B2 AU 757945B2 AU 34361/99 A AU34361/99 A AU 34361/99A AU 3436199 A AU3436199 A AU 3436199A AU 757945 B2 AU757945 B2 AU 757945B2
Authority
AU
Australia
Prior art keywords
cbd
cannabidiol
mice
cells
cannabinoids
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
AU34361/99A
Other languages
English (en)
Other versions
AU3436199A (en
Inventor
Marc Feldmann
Ruth Gallily
Anne-Marie Malfait
Raphael Mechoulam
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Kennedy Trust for Rheumatology Research
Yissum Research Development Co of Hebrew University of Jerusalem
Original Assignee
Kennedy Institute of Rheumotology
Mathilda and Terence Kennedy Institute of Rheumatology
Yissum Research Development Co of Hebrew University of Jerusalem
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Kennedy Institute of Rheumotology, Mathilda and Terence Kennedy Institute of Rheumatology, Yissum Research Development Co of Hebrew University of Jerusalem filed Critical Kennedy Institute of Rheumotology
Publication of AU3436199A publication Critical patent/AU3436199A/en
Application granted granted Critical
Publication of AU757945B2 publication Critical patent/AU757945B2/en
Anticipated expiration legal-status Critical
Ceased legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/658—Medicinal preparations containing organic active ingredients o-phenolic cannabinoids, e.g. cannabidiol, cannabigerolic acid, cannabichromene or tetrahydrocannabinol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Pulmonology (AREA)
  • Epidemiology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Rheumatology (AREA)
  • Hospice & Palliative Care (AREA)
  • Dermatology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Pain & Pain Management (AREA)
  • Psychiatry (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines Containing Plant Substances (AREA)
  • Pyrane Compounds (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
AU34361/99A 1998-04-14 1999-04-14 Use of cannabinoids as anti-inflammatory agents Ceased AU757945B2 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
GBGB9807639.1A GB9807639D0 (en) 1998-04-14 1998-04-14 Anti-inflammatory agents
GB9807639 1998-04-14
PCT/GB1999/001140 WO1999052524A1 (en) 1998-04-14 1999-04-14 Use of cannabinoids as anti-inflammatory agents

Publications (2)

Publication Number Publication Date
AU3436199A AU3436199A (en) 1999-11-01
AU757945B2 true AU757945B2 (en) 2003-03-13

Family

ID=10830115

Family Applications (1)

Application Number Title Priority Date Filing Date
AU34361/99A Ceased AU757945B2 (en) 1998-04-14 1999-04-14 Use of cannabinoids as anti-inflammatory agents

Country Status (12)

Country Link
US (1) US6410588B1 (https=)
EP (1) EP1071417B1 (https=)
JP (1) JP2002511411A (https=)
AT (1) ATE288749T1 (https=)
AU (1) AU757945B2 (https=)
CA (1) CA2328368C (https=)
DE (1) DE69923671T2 (https=)
DK (1) DK1071417T3 (https=)
ES (1) ES2241277T3 (https=)
GB (1) GB9807639D0 (https=)
IL (1) IL138979A0 (https=)
WO (1) WO1999052524A1 (https=)

Families Citing this family (60)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU766988B2 (en) 1998-04-21 2003-10-30 Government Of The United States Of America, As Represented By The Secretary Of The Department Of Health And Human Services, The Cannabinoids as antioxidants and neuroprotectants
BR0009200A (pt) 1999-03-22 2001-12-26 Immugen Pharmaceuticals Inc Compostos e composições para o tratamento dedoenças associada com disfunção imune
US6566560B2 (en) 1999-03-22 2003-05-20 Immugen Pharmaceuticals, Inc. Resorcinolic compounds
ES2256305T3 (es) * 2000-10-31 2006-07-16 Pharma Mar, S.A. Formulaciones de kahalalide f.
EP1206934A1 (en) * 2000-11-15 2002-05-22 B. Braun Melsungen Ag Blockade of sodium channels by phenol derivatives
US10004684B2 (en) 2001-02-14 2018-06-26 Gw Pharma Limited Pharmaceutical formulations
GB0202385D0 (en) * 2002-02-01 2002-03-20 Gw Pharma Ltd Compositions for the treatment of nausea,vomiting,emesis,motion sicknes or like conditions
EP1482917B1 (en) * 2002-02-01 2019-05-08 GW Pharma Limited Compositions comprising cannabidiolic acid for treatment of nausea, vomiting, emesis, motion sickness or like conditions
IL148244A0 (en) 2002-02-19 2002-09-12 Yissum Res Dev Co Anti-nausea and anti-vomiting activity of cannabidiol compounds
AU2003217961B2 (en) 2002-03-08 2008-02-28 Signal Pharmaceuticals, Llc Combination therapy for treating, preventing or managing proliferative disorders and cancers
SI1542657T1 (sl) * 2002-08-14 2012-04-30 Gw Pharma Ltd Kanabinoidne kapljevite formulacije za sluzniäśno administracijo
US7067155B2 (en) * 2003-01-03 2006-06-27 Tbni, Inc. Anti-inflammatory humate compositions and methods of use thereof
IL160420A0 (en) * 2004-02-16 2004-07-25 Yissum Res Dev Co Treating or preventing diabetes with cannabidiol
WO2006024958A2 (en) * 2004-08-09 2006-03-09 Novimmune S.A. Cannabinoid compositions and methods of use thereof
US8911751B2 (en) * 2005-10-11 2014-12-16 Yissum Research Development Company Of The Hebrew University Of Jerusalem Compositions for nasal delivery
US20100158973A1 (en) 2006-03-13 2010-06-24 Hadasit Medical Research Services & Development Llimited Therapeutic uses of cannabidiol compounds
GB2438682A (en) * 2006-06-01 2007-12-05 Gw Pharma Ltd New use for cannabinoids
GB2448535A (en) * 2007-04-19 2008-10-22 Gw Pharma Ltd New use for cannabinoid-containing plant extracts
GB2450741A (en) * 2007-07-05 2009-01-07 Gw Pharma Ltd Cannabinoid containing plant extracts in the treatment of inflammatory bowel disease
ES2359168T3 (es) * 2007-10-02 2011-05-19 Vivacell Biotechnology España S.L. Composición que comprende cannabinoides no psicotrópicos para el tratamiento de enfermedades antiinflamatorias.
GB2496688B (en) 2011-11-21 2016-06-29 Gw Pharma Ltd Tetrahydrocannabivarin for use in the treatment of intestinal inflammatory diseases
US9956182B2 (en) 2013-05-02 2018-05-01 Mor Research Applications Ltd. Cannabidiol for the prevention and treatment of graft-versus-host disease
US9889100B2 (en) 2013-05-02 2018-02-13 Mor Research Applications Ltd. Cannabidiol for treatment of severe and refractory graft-versus-host disease
US10172786B2 (en) * 2014-12-16 2019-01-08 Axim Biotechnologies, Inc. Oral care composition comprising cannabinoids
EP3277260B1 (en) 2015-04-01 2021-05-12 The State of Israel, Ministry of Agriculture & Rural Development, Agricultural Research Organization (ARO) (Volcani Center) Erodium crassifolium l'her plant extracts and uses thereof
US12303541B2 (en) 2015-04-01 2025-05-20 The State Of Israel, Ministry Of Agriculture & Rural Development, Agricultural Research Organization (Aro) (Volcani Center) Erodium crassifolium L'Her plant extracts and uses thereof
US9585867B2 (en) 2015-08-06 2017-03-07 Charles Everett Ankner Cannabinod formulation for the sedation of a human or animal
WO2017066747A1 (en) * 2015-10-16 2017-04-20 Scythian Biosciences Inc. Methods and compositions for treating gastrointestinal inflammation
WO2017160923A1 (en) * 2016-03-15 2017-09-21 Royal Oil Colorado Llc Formulations of argan oil and cannabidiol
US10499584B2 (en) 2016-05-27 2019-12-10 New West Genetics Industrial hemp Cannabis cultivars and seeds with stable cannabinoid profiles
US10399920B2 (en) 2016-06-01 2019-09-03 S&B Pharma, Inc. Crystalline form of cannabidiol
GB2551985B (en) * 2016-07-01 2019-01-30 Gw Res Ltd Novel formulation
GB2551987A (en) 2016-07-01 2018-01-10 Gw Res Ltd Oral cannabinoid formulations
WO2018064654A1 (en) 2016-10-01 2018-04-05 James Smeeding Pharmaceutical compositions comprising a statin and a cannabinoid and uses thereof
EP3534893A1 (en) 2016-11-02 2019-09-11 To Pharmaceuticals LLC Combination therapy of cbd and copaxone
EP3592346A4 (en) 2017-03-05 2020-12-30 The State of Isreal, Ministry of Agriculture & Rural Development, Agricultural Research Organization (ARO) COMPOSITIONS AND METHODS FOR THE TREATMENT OF CANCER
WO2019014851A1 (zh) * 2017-07-18 2019-01-24 汉义生物科技（北京）有限公司 大麻二酚在治疗肺动脉高压中的应用
IL301622A (en) * 2017-08-14 2023-05-01 Zynerba Pharmaceuticals Inc Methods for treating degenerative joint disease with cannabidiol gel through the skin
US11110056B1 (en) 2018-05-03 2021-09-07 Actual Natural Health & Wellness Products, Inc. Nasal hygiene method and composition
US10945982B1 (en) * 2018-05-03 2021-03-16 Paul A. Lobel Nasal hygiene method and composition
JP2021526556A (ja) 2018-05-30 2021-10-07 ダイレクト バイオロジクス エルエルシー 成長因子および細胞外小胞を凍結または粉状にした、間葉系幹細胞（ｍｓｃ）の調製物を含む助剤、ならびにその使用方法
EP3866781A4 (en) * 2018-10-16 2022-11-09 Systamedic Inc. NOVEL COMPOSITION FOR THE TREATMENT OF INFLAMMATORY DISEASES
US11026888B1 (en) 2019-01-04 2021-06-08 Nutrition Therapeutics, Inc. Functional beverage compositions and methods of using and making same
AU2019424226B2 (en) * 2019-01-24 2023-06-29 Hanyi Bio-Technology Company Ltd. Use of geranylflavone A in preparation of drug for promoting healing of wounds
BR112021015549A2 (pt) 2019-02-07 2021-10-26 Direct Biologics Llc Método para tratar osteoartrite com uma combinação de exossomos de células tronco mesenquimais, células tronco mesenquimais sinoviais e andaimes
WO2020167751A1 (en) * 2019-02-11 2020-08-20 Chancey John Methods of making and using phytocannabinoids complexed with a protein, peptide, amino acid, polysaccharide, disaccharide, ormonosaccharide
WO2020223510A1 (en) * 2019-04-30 2020-11-05 Greenway Herbal Products, Llc Cannabinoid compositions and methods of using
CA3146433A1 (en) 2019-07-18 2021-01-21 Direct Biologics Llc Preparations comprising mesenchymal stem cells and cannabinoids and methods of their use
AU2021250462A1 (en) * 2020-04-02 2022-12-01 Incannex Healthcare Limited Methods and compositions for treating or preventing an inflammatory condition
US12590310B2 (en) 2020-04-22 2026-03-31 Direct Biologics, Llc Methods and compositions for treating inflammatory conditions associated with infectious disease
IL298062A (en) * 2020-05-11 2023-01-01 Add Advanced Drug Delivery Tech Ltd Uses and formulations of cannabinoids
IL298059A (en) * 2020-05-11 2023-01-01 Add Advanced Drug Delivery Tech Ltd Uses and formulations of cannabinoids
CA3199891A1 (en) 2020-11-24 2022-06-02 Ruth Gallily Cannabinoid derivatives and their use for the treatment of inflammation and/or pain and/or obesity
IL309886A (en) * 2021-07-15 2024-03-01 Incannex Healthcare Ltd A preparation containing cannabidiol and hydroxychloroquine in a combined capsule at a fixed dose
WO2023096918A1 (en) * 2021-11-27 2023-06-01 Miralogx Llc Synthetic cannabinoid compounds, pharmaceutical compositions, and treatment methods
CA3244798A1 (en) 2022-02-21 2023-08-24 Universidade Nova De Lisboa COMPOUNDS AND COMPOSITIONS AGAINST NEURODEGENERATIVE DISEASES
EP4230201A1 (en) 2022-02-21 2023-08-23 Universidade Nova De Lisboa Composition for treating neurodegenerative diseases
WO2024033521A1 (en) 2022-08-12 2024-02-15 GW Research Limited Oral solid dosage forms comprising cannabinoids
US12502407B2 (en) 2024-04-25 2025-12-23 Direct Biologics, Llc Treatment of fistula with bone marrow mesenchymal stem cell derived extracellular vesicles
WO2025259202A1 (en) * 2024-06-12 2025-12-18 Chiang Mai University A method of reprogramming human somatic cells and reprogrammed cells derived thereof

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4847290A (en) * 1987-08-17 1989-07-11 Sumner Burstein Delta 1-thc-7-oic acid and analgesic and anti-inflammatory agents
US5338753A (en) * 1992-07-14 1994-08-16 Sumner H. Burstein (3R,4R)-Δ6 -tetrahydrocannabinol-7-oic acids useful as antiinflammatory agents and analgesics

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IL48824A (en) 1976-01-12 1980-05-30 Yissum Res Dev Co Pharmaceutical compositions containing (3s,js) tetrahydrocanabinol derivatives and some novel compounds of this type
US4973603A (en) * 1988-06-16 1990-11-27 Sumner Burstein Platelet activating factor antagonist and methods of use therefor
US5521215A (en) * 1989-11-07 1996-05-28 Ramot University Authority For Applied Research And Industrial Development Ltd. NMDA-blocking pharmaceuticals

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4847290A (en) * 1987-08-17 1989-07-11 Sumner Burstein Delta 1-thc-7-oic acid and analgesic and anti-inflammatory agents
US5338753A (en) * 1992-07-14 1994-08-16 Sumner H. Burstein (3R,4R)-Δ6 -tetrahydrocannabinol-7-oic acids useful as antiinflammatory agents and analgesics

Also Published As

Publication number Publication date
ATE288749T1 (de) 2005-02-15
DE69923671T2 (de) 2006-03-16
AU3436199A (en) 1999-11-01
ES2241277T3 (es) 2005-10-16
CA2328368A1 (en) 1999-10-21
WO1999052524A1 (en) 1999-10-21
CA2328368C (en) 2009-03-31
DK1071417T3 (da) 2005-06-13
EP1071417A1 (en) 2001-01-31
IL138979A0 (en) 2001-11-25
GB9807639D0 (en) 1998-06-10
DE69923671D1 (de) 2005-03-17
US6410588B1 (en) 2002-06-25
JP2002511411A (ja) 2002-04-16
EP1071417B1 (en) 2005-02-09

Similar Documents

Publication Publication Date Title
AU757945B2 (en) Use of cannabinoids as anti-inflammatory agents
Wang et al. Angelica sinensis polysaccharide attenuates CCl4-induced liver fibrosis via the IL-22/STAT3 pathway
JP2005501094A (ja) トコフェロール富化組成物および炎症性症状の回復
Gürbüz et al. Evaluation of the anti-ulcerogenic effect of sesquiterpene lactones from Centaurea solstitialis L. ssp. solstitialis by using various in vivo and biochemical techniques
Tong et al. Norisoboldine ameliorates collagen-induced arthritis through regulating the balance between Th17 and regulatory T cells in gut-associated lymphoid tissues
IL194987A (en) Use of PIF peptide to produce a drug to regulate the immune system
EP2060255B1 (en) Compositions for prevention and treatment of inflammatory disease, autoimmune disease, and transplant rejection
CN101843629A (zh) 淫羊藿苷和含有淫羊藿苷的淫羊藿黄酮的新用途
KR100261114B1 (ko) 히스톤을 함유하는 류마티스 관절염 치료제 조성물
Song et al. lnterleukin-2-lnduced Changes in Behavioural, Neurotransmitter, and Immunological Parameters in the Olfactory Bulbectomized Rat
Dai et al. Toll‐Like Receptor 4–Myeloid Differentiation Primary Response Gene 88 Pathway Is Involved in the Shikonin Treatment of CIA by Regulating Treg/Th17 Expression
PT2120919E (pt) Nova combinação para utilização no tratamento de perturbações inflamatórias
US20140221472A1 (en) Use of myricetin or derivatives thereof as a cathepsin k inhibitor
JP7612025B2 (ja) 敗血症を治療するための薬物組成物及びその使用
CN109939119B (zh) 栀子苷在制备治疗多发性硬化症药物中的应用
Bourne Cholera enterotoxin: failure of anti-inflammatory agents to prevent cyclic AMP accumulation
WO2017039751A1 (en) Mutant peptides and methods of treating subjects using the same
KR20000048821A (ko) 관절염의 치료를 위해 비타민 ｄ 유사체를 사용하는 방법
WO2006024958A2 (en) Cannabinoid compositions and methods of use thereof
JP6861162B2 (ja) アポエクオリン含有組成物および神経細胞の炎症を治療するためのアポエクオリンの使用方法
WO2014193269A2 (ru) Лекарственное средство на основе дииндолилметана и его применение для лечения гриппа и респираторных вирусных инфекций
Mahmoud et al. Biochemical and histopathological aspects of Nandrolone decanoate nephrotoxicity and potential impact of alpha lipoic acid
RU2763761C1 (ru) Гепатопротекторное гуминовое средство
EP4523684A1 (en) Compositions comprising lipoxin-a4 and maresin-1, and uses thereof
RU2256460C2 (ru) Способ лечения неспецифической бронхопневмонии у телят

Legal Events

Date Code Title Description
FGA Letters patent sealed or granted (standard patent)